Sensorium Therapeutics Inc. has identified mesembrine analogues acting as serotonin transporter (SERT) inhibitors reported to be useful for the treatment of neurological disorders.

Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has synthesized cytochrome P450 11B2, mitochondrial (CYP11B2; aldosterone synthase; ALDOS) inhibitors reported to be useful for the treatment of hypertension, diabetic nephropathy, chronic kidney disease and primary aldosteronism.

Transition Bio Ltd. has disclosed YTH domain-containing protein 1 (YTHDC1; YT521-B) inhibitors reported to be useful for the treatment of acute myeloid leukemia (AML).

Nanjing Synnocare Pharmaceutical Technology Co. Ltd. has described poly(ADP-ribose) glycohydrolase (PARG) inhibitors reported to be useful for the treatment of cancer.

Galapagos NV has divulged probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) inhibitors reported to be useful for the treatment of cancer.

Astellas Engineered Small Molecules US Inc. has identified poly(ADP-ribose) polymerase (PARP) inhibitors, particularly PARP-1 (ARTD1), reported to be useful for the treatment of neuronal injury.

Kangbaida (Sichuan) Biotechnology Co. Ltd. has synthesized pyrrolidine derivatives acting as Toll-like receptor 7 (TLR7) and/or (TLR8) antagonists reported to be useful for the treatment of autoimmune disease.

Rednvia Co. Ltd. has disclosed alkaline phosphatase tissue-nonspecific isozyme (TNAP) inhibitors reported to be useful for the treatment of ectopic calcification.

Gan & Lee Pharmaceuticals Co. Ltd. has described protein cereblon (CRBN) inhibitors and proteolysis targeting chimera (PROTAC) compounds reported to be useful for the treatment of cancer.

Treeline Biosciences Inc. has divulged proteolysis targeting chimeras (PROTACs) comprising cereblon (CRBN) ligands coupled to a Bcl-2-like protein 1 (Bcl-xl; Bcl-X; BCL2L1) targeting moiety via a linker acting as Bcl-xl degradation inducers reported to be useful for the treatment of cancer.